Popular Trials
Virus Therapy
LAIV for Flu
This trial is testing the hypothesis that the T-bet expressing fraction of flu-specific B cells after receiving the live attenuated influenza vaccine (LAIV) serves as an early biomarker of long-lived antibody responses after vaccination.
Anti-metabolites
Radiation Therapy + Fluorouracil for Rectal Cancer
This trial tests if combining radiation therapy with chemotherapy can shrink tumors in patients with stage II or III rectal cancer. The treatment aims to make tumors smaller and easier to remove while protecting normal cells. The study will also look at the timing of treatments and their effects on surgery and recovery.
Popular Filters
Trials for Influenza Patients
Virus Vaccine
Inactivated Influenza A/H5N1 Vaccine for Influenza
This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.
Interferon
Interferon alfacon-1 for Influenza
A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating Influenza Viruses. The use of Interferon-alfacon1 as a co-treatment along with the standard of care antiviral is hypothesized to be safe. Clinical improvement of patients is hypothesized to be quicker.
Behavioral Intervention
Control Group +1 More for Influenza
During the 2010-2011 and the 2011-2012 seasonal influenza immunization campaigns, we will recruit a minimum of 46 healthcare organizations to either conduct their campaigns as usual or to use the "Successful Influenza Immunization Campaigns for Healthcare Personnel: A Guide for Campaign Planners and a web-based grab-and-go Tool Kit. At the end of the campaign season we will evaluate the impact of the Guide and web-based tools and assess whether there were changes in immunization rates within each organization and/or if there were significant changes in the management of the campaigns across organizations. Following completion of the study, we will work with partner organizations to make these tools available to all Canadian healthcare organizations.
Probiotic
Bifidobacterium lactis HN019 for Influenza
To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
Vaccine
HD Vaccine +1 More for Influenza
The purpose of this study is to prospectively evaluate relative effectiveness of high dose influenza vaccine in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the standard dose trivalent seasonal influenza vaccine.
Group B for Influenza
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As part of their vaccination campaign, the CDC strongly encourages inpatients to be vaccinated prior to hospital discharge. Accordingly, Stony Brook Hospital has enacted a policy that mandates screening all hospital inpatients for vaccination prior to discharge. While physicians or patients can opt not to vaccinate, the default is to proceed. Surgical oncologists have several concerns about vaccinating their patients after major surgical procedures. Patients with cancer have impaired immunity, and the ability of our patients to mount an effective immune response to the vaccine is unclear. Conversely, due to their immunocompromised state, our patients may be more susceptible to complications from the vaccine, such as influenza-like-illness (ILI), or have higher rates of postoperative complications due to the additional immune challenge of the vaccine. Previous studies have evaluated the flu vaccine in patients receiving chemotherapy, or after organ transplantation, but the combination of cancer and major surgery remains unstudied. This is a collaborative study with Infectious Diseases and Microbiology to evaluate the response to the flu vaccine in patients with pancreatic or gastric cancer, soft tissue sarcoma or peritoneal surface disease (i.e. carcinomatosis from appendiceal or colon cancers). Patients will be randomly selected to receive the vaccine either 2 weeks preoperatively or postoperatively at the time of discharge. Serum antibody response, rates of ILI and post-op complications will be analyzed. The long term goal of this study is two-fold: to determine the optimal time to vaccinate this group of patients in relation to their surgery, and to improve compliance with vaccination.
Trials for Prolymphocytic Leukemia Patients
Alkylating agents
Cord Blood Transplant + Chemo/Radiation for Leukemia and Lymphoma
This trial is testing whether giving an umbilical cord blood transplant together with chemotherapy and radiation therapy works better than just giving an umbilical cord blood transplant for treating patients with hematologic disease.
Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
Anti-tumor antibiotic
Chemotherapy Combination for Leukemia
This trial is testing a combination of drugs to treat patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. The drugs work in different ways to stop the growth of cancer cells.
Proteasome Inhibitor
Chemotherapy + Stem Cell Transplant for Multiple Myeloma
This trial is studying the side effects and best dose of bortezomib when given together with fludarabine phosphate and melphalan with or without total marrow irradiation for patients with high-risk stage I or II multiple myeloma.
Phase 3 Trials
Anti-metabolites
Chemotherapy for Pancreatic Cancer
This trial is studying gemcitabine hydrochloride given with or without erlotinib hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil, to see how well it works in treating patients with pancreatic cancer that has been removed by surgery.
[18F]-Fluorodeoxyglucose for Tumors
This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.
Trials Offering Remuneration
Virus Vaccine
Inactivated Influenza A/H5N1 Vaccine for Influenza
This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.
Selective Estrogen Receptor Modulator
MF101 for Hot Flashes
This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.
Cytokine
Interferon Gamma 1b for Adverse Effects of Interferon Therapy
The most frequent side effects associated with Actimmune (interferon gamma 1b) therapy are the occurrence of 'flu-like symptoms' (FLS),which might include fever, chills, muscle aches, and tiredness. Earlier studies have demonstrated that these symptoms are common in healthy volunteers as well as in patients. This study is designed to determine whether a titration of dosing reduces the frequency and severity of the FLS. A reported study with another interferon (interferon beta), demonstrated a reduction in the frequency and severity of the FLS when a titration of dosing was used. This study will compare the effects of the standard dose regimen with a titration regimen in healthy volunteers.
Vaccine
TIV for Influenza
This is a phase 1, research study is looking at the safety and acceptability of a new vaccine adjuvant (immune booster) called PAL when combined with the seasonal flu vaccine (Fluviral) to test the safety and effectiveness of new vaccines and medications on healthy volunteers. The study will enroll approximately 48 healthy adult participants, and occur over 3 years. In the first six months/180 days of the study participants will have visits to the study site during which safety and immunogenicity outcomes will be measured. From Day 181 to Year 3, participants will be contacted by telephone or email to collect information on any adverse events.
View More Related Trials
Frequently Asked Questions
Introduction to flu
What are the top hospitals conducting flu research?
When it comes to combating the ever-evolving flu virus, several hospitals across the United States are leading the way in clinical trials. In Birmingham, Alabama, the University of Alabama at Birmingham is making strides with three active flu trials and a total of eight conducted since their first recorded trial back in 2005. Meanwhile, in Houston's M D Anderson Cancer Center, researchers are focusing on the intersection between cancer and influenza with three ongoing studies. Although they have only recently started exploring flu trials in 2021, this renowned center is committed to uncovering new insights into this viral infection.
Heading north to Chicago brings us to GSK Investigational Site—an institution dedicated specifically to investigational research—with two active flu trials and five completed studies since its inception in 2008. Further westward lies Meridian Clinical Research, LLC based in Omaha—a facility that has been actively involved with influenza research for quite some time. With two current trials underway and an impressive twelve completed studies dating back to 2004, their contributions have proven invaluable towards understanding and finding effective treatments for the flu virus.
Lastly but not least important on our list is St. Joseph's Hospital and Medical Center located amidst Phoenix's vibrant landscape which like MD Anderson Cancer Centers just entering into conducting these crucial examinations; as recent as2022 where starting off by recording one significant breakthrough after another having already initiated two new experiments already.The dedication exhibited by these top hospitals demonstrates a commitment to tackling one of humanity's most persistent health challenges—the seasonal influenza virus—and ultimately striving toward alleviating its impact worldwide.
Which are the best cities for flu clinical trials?
When it comes to flu clinical trials, several cities emerge as prominent hubs for research. Miami, Florida leads the pack with 23 ongoing trials focusing on a variety of interventions including bivalent BNT162b2 + QIV and Quadrivalent Influenza mRNA Vaccine MRT5407. Columbus, Ohio closely follows with 14 active trials exploring topics such as quality-of-life assessment and BLI5100 High Dose. San Diego, California and Los Angeles, California both have 13 active flu trials each that investigate different treatments like Fluorouracil and Enhanced Text Reminders. Lastly, Phoenix, Arizona boasts 12 active studies examining potential breakthroughs like Quadrivalent influenza modRNA vaccine and Ofatumumab. These cities offer individuals an opportunity to participate in cutting-edge research aimed at improving flu prevention and treatment strategies.
Which are the top treatments for flu being explored in clinical trials?
Researchers are actively investigating various treatments to combat the flu in clinical trials. Among them, three leading contenders have emerged:
- Baloxavir marboxil: Currently being explored in 8 active trials for the flu.
- Favipiravir: Under investigation in 6 ongoing clinical trials targeting influenza.
- Lopinavir/ritonavir: Being evaluated in 4 active studies as a potential treatment option for the flu. These promising candidates offer hope for improved management and prevention of this widespread illness.
What are the most recent clinical trials for flu?
Recent clinical trials have been conducted to explore new treatments and strategies for managing the flu. Phase 4 trial of Group i, which became available on 9/15/2023, holds promise in enhancing our understanding of the virus and its treatment options. Additionally, a Phase 3 trial called Treatment Period 1 (available from 9/5/2023) is investigating potential interventions for flu. Another noteworthy study is SPR720 (Phase 1), which became available on 8/1/2023, offering insights into novel approaches to combatting this contagious respiratory illness. These trials contribute to ongoing efforts aimed at improving prevention measures and developing more effective treatments against the flu.
What flu clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of flu research, paving the way for improved prevention and treatment options. Among these breakthroughs is a trial conducted by Seqirus, which tested the efficacy of Experimental: aIIV-B Investigational as a single intramuscular dose on Day 1, completing in August 2022. Additionally, Seqirus completed another trial involving aH5N6c on Day 22 in July 2022. Notably, FluGen Inc's Cam2020 M2SR H3N2 influenza vaccine study concluded successfully in June 2022. These trials represent important advancements that contribute to our understanding and management of flu-related illnesses.